Piramal Pharma’s US Facility Receives Successful Closure of FDA Inspection

Piramal Pharma’s US Facility Receives Successful Closure of FDA Inspection​

Piramal Pharma Ltd has announced that its manufacturing facility located in Sellersville, USA, has successfully closed the inspection process conducted by the U.S. Food and Drug Administration (US FDA).

The company confirmed that the US FDA issued an Establishment Inspection Report (EIR) for the specific manufacturing site. The successful conclusion of the inspection marks a key operational achievement for Piramal Pharma’s overseas operations.

PPLPHARMA Stock Price Movement​

As shares of Piramal Pharma Limited edge higher in live trading, the stock stands at ₹174.60, up 3.86% by 11:11 AM. The company sees robust activity as over 5.08 million shares are traded during this brisk morning session.

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.